Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.

Literature DB >> 20855730

In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.

Ji-Woong Jeong¹, Sung-Ji Jung, Hyun-Hee Lee, Yong-Zu Kim, Tae-Kyo Park, Young-Lag Cho, Sang-Eun Chae, Sung-Yoon Baek, Sung-Ho Woo, Hyang-Sook Lee, Jin-Hwan Kwak.

Abstract

LCB01-0371 is a new oxazolidinone with cyclic amidrazone. In vitro activity of LCB01-0371 against 624 clinical isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics. LCB01-0371 showed good activity against Gram-positive pathogens. In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated. LCB01-0371 was more active than linezolid against these systemic infections. LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20855730 PMCID： PMC2981296 DOI： 10.1128/AAC.00723-10

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

7 in total

1. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Authors: Inmaculada A Herrero; Nicolas C Issa; Robin Patel
Journal: N Engl J Med Date: 2002-03-14 Impact factor: 91.245

Review 2. Linezolid: a review of its use in the management of serious gram-positive infections.

Authors: C M Perry; B Jarvis
Journal: Drugs Date: 2001 Impact factor: 9.546

3. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors: R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal: Lancet Date: 2001-04-14 Impact factor: 79.321

4. Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors: S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal: Lancet Date: 2001-07-21 Impact factor: 79.321

5. Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors: R S Schwalbe; J T Stapleton; P H Gilligan
Journal: N Engl J Med Date: 1987-04-09 Impact factor: 91.245

6. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.

Authors: I-Nae Park; Sang-Bum Hong; Yeon-Mok Oh; Mi-Na Kim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Dong Soon Kim; Won Dong Kim; Tae Sun Shim
Journal: J Antimicrob Chemother Date: 2006-07-19 Impact factor: 5.790

7. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.

Authors: Karen L Leach; Steven M Swaney; Jerry R Colca; William G McDonald; James R Blinn; Lisa M Thomasco; Robert C Gadwood; Dean Shinabarger; Liqun Xiong; Alexander S Mankin
Journal: Mol Cell Date: 2007-05-11 Impact factor: 17.970

7 in total

19 in total

Review 1. Investigational antimicrobial agents of 2013.

Authors: Michael J Pucci; Karen Bush
Journal: Clin Microbiol Rev Date: 2013-10 Impact factor: 26.132

Review 2. Antibiotics in the clinical pipeline at the end of 2015.

Authors: Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal: J Antibiot (Tokyo) Date: 2016-06-29 Impact factor: 2.649

3. Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.

Authors: Zhaojing Zong; Wei Jing; Jin Shi; Shu'an Wen; Tingting Zhang; Fengmin Huo; Yuanyuan Shang; Qian Liang; Hairong Huang; Yu Pang
Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191

4. In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.

Authors: Shaochen Guo; Bin Wang; Lei Fu; Xi Chen; Weiyan Zhang; Haihong Huang; Yu Lu
Journal: Antimicrob Agents Chemother Date: 2021-08-16 Impact factor: 5.191

5. Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure.

Authors: Mahesh S Deshmukh; Nidhi Jain
Journal: ACS Med Chem Lett Date: 2017-09-28 Impact factor: 4.345

6. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.

Authors: Tae Sung Kim; Jin Ho Choe; Young Jae Kim; Chul-Su Yang; Hyun-Jin Kwon; Jinsun Jeong; Guehye Kim; Da Eun Park; Eun-Kyeong Jo; Young-Lag Cho; Jichan Jang
Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191

Review 7. Investigational drugs to treat methicillin-resistant Staphylococcus aureus.

Authors: Cuong Vuong; Anthony J Yeh; Gordon Y C Cheung; Michael Otto
Journal: Expert Opin Investig Drugs Date: 2015-11-04 Impact factor: 6.206

8. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers.

Authors: Yong-Soon Cho; Hyeong-Seok Lim; Shi-Hyang Lee; Young Lag Cho; Hee-Sook Nam; Kyun-Seop Bae
Journal: Antimicrob Agents Chemother Date: 2018-06-26 Impact factor: 5.191

9. In Vitro Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Authors: Dae Hun Kim; Su-Young Kim; Won-Jung Koh; Byung Woo Jhun
Journal: Antimicrob Agents Chemother Date: 2021-06-17 Impact factor: 5.191

Review 10. New Drugs for the Treatment of Tuberculosis.

Authors: Elisa H Ignatius; Kelly E Dooley
Journal: Clin Chest Med Date: 2019-12 Impact factor: 4.967